CA2060507A1 - Compositions anticoagulantes a base de facteur xa - Google Patents

Compositions anticoagulantes a base de facteur xa

Info

Publication number
CA2060507A1
CA2060507A1 CA2060507A CA2060507A CA2060507A1 CA 2060507 A1 CA2060507 A1 CA 2060507A1 CA 2060507 A CA2060507 A CA 2060507A CA 2060507 A CA2060507 A CA 2060507A CA 2060507 A1 CA2060507 A1 CA 2060507A1
Authority
CA
Canada
Prior art keywords
factor
inactivated
vivo
active
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2060507A
Other languages
English (en)
Other versions
CA2060507C (fr
Inventor
Charles T. Esmon
Fletcher B. Taylor, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Howard Hughes Medical Institute
Charles T. Esmon
Fletcher B. Taylor, Jr.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, Charles T. Esmon, Fletcher B. Taylor, Jr. filed Critical Oklahoma Medical Research Foundation
Publication of CA2060507A1 publication Critical patent/CA2060507A1/fr
Application granted granted Critical
Publication of CA2060507C publication Critical patent/CA2060507C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002060507A 1989-06-14 1990-06-06 Compositions anticoagulantes a base de facteur xa Expired - Fee Related CA2060507C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/367,544 US5120537A (en) 1989-06-14 1989-06-14 Factor xa based anticoagulant compositions
US367,544 1989-06-14

Publications (2)

Publication Number Publication Date
CA2060507A1 true CA2060507A1 (fr) 1990-12-15
CA2060507C CA2060507C (fr) 1996-12-10

Family

ID=23447608

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002060507A Expired - Fee Related CA2060507C (fr) 1989-06-14 1990-06-06 Compositions anticoagulantes a base de facteur xa

Country Status (10)

Country Link
US (1) US5120537A (fr)
EP (1) EP0477274B1 (fr)
JP (1) JPH0784392B2 (fr)
AT (1) ATE101796T1 (fr)
AU (1) AU630477B2 (fr)
CA (1) CA2060507C (fr)
DE (1) DE69006851T2 (fr)
DK (1) DK0477274T3 (fr)
ES (1) ES2063365T3 (fr)
WO (1) WO1990015619A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS136091A3 (en) * 1990-05-10 1992-04-15 Zymo Genetics Agents for determining thrombi and their application
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US20040072757A1 (en) * 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
WO1993007491A1 (fr) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska Methode en un temps base sur la thrombomoduline soluble de determination de l'etat de proteines inhibant la coagulation dependante de la vitamine k
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5266462A (en) * 1992-06-03 1993-11-30 Baxter Diagnostics Inc. Measurement of platelet activities
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
IL149398A0 (en) * 1999-11-02 2002-11-10 Aventis Pharma Gmbh USE OF RUSSELL'S VIPER VENOM-INDUCED PLASMA FACTOR Xa ACTIVITY TO MONITOR THE ACTIVITY OF FACTOR Xa INHIBITORS
WO2001051067A1 (fr) * 2000-01-13 2001-07-19 Baxter International Inc. Composition anticoagulante a facteurs sanguins inactives multiples
AU2002359790A1 (en) * 2001-12-21 2003-07-15 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
AU2003237870A1 (en) * 2002-06-07 2003-12-22 The Brigham & Women's Hospital, Inc. Method and composition for inhibing or slowing blood coagulation
US7771956B2 (en) * 2003-06-30 2010-08-10 Brigham & Women's Hospital, Inc. Method for detecting the presence of a phospholipid
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
SG185263A1 (en) * 2007-09-28 2012-11-29 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
EP0430930B1 (fr) * 1985-03-15 1993-09-01 Btg International Limited Protéine facteur IX
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii

Also Published As

Publication number Publication date
ES2063365T3 (es) 1995-01-01
CA2060507C (fr) 1996-12-10
DE69006851D1 (de) 1994-03-31
JPH0784392B2 (ja) 1995-09-13
ATE101796T1 (de) 1994-03-15
DE69006851T2 (de) 1994-06-30
DK0477274T3 (da) 1994-03-28
WO1990015619A1 (fr) 1990-12-27
US5120537A (en) 1992-06-09
JPH04505765A (ja) 1992-10-08
AU630477B2 (en) 1992-10-29
AU5922690A (en) 1991-01-08
EP0477274A1 (fr) 1992-04-01
EP0477274B1 (fr) 1994-02-23

Similar Documents

Publication Publication Date Title
CA2060507A1 (fr) Compositions anticoagulantes a base de facteur xa
Hedner et al. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
AU607303B2 (en) Composition of anticoagulants
Sherry et al. Studies on the fibrinolytic enzyme of human plasma
Rosenberg Heparin, antithrombin, and abnormal clotting
NZ510509A (en) Compounds that specifically inhibit factor VIIa activity used to inhibit blood clotting and inflammatory response
Esnouf et al. Enzymology and the blood clotting mechanism
EP0521873A4 (en) Anticoagulant proteins
WO1979000853A1 (fr) Produit medicinal pour organe circulatoire
AU8452991A (en) 1-aryl-3-pyridinyl-2-propene-1-ones
Broze Jr et al. The role of factor XI in coagulation
CA2101614A1 (fr) Peptides synthetiques derives de la vitronectine et composes pharmaceutiques en contenant
US5817309A (en) Antidote for hirudin and synthetic thrombin inhibitors and method of use
Kini et al. Inhibition of platelet aggregation by a fibrinogenase from Naja nigricollis venom is independent of fibrinogen degradation
CA2452395A1 (fr) Compositions hemostatiques pharmaceutiquement stables
Katsuura et al. Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
AU7044391A (en) Stabilization of k2p pro
Kazama et al. Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4: role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein
AU7037591A (en) Stabilization of t-pa pro
Esnouf et al. Biochemical aspects of blood coagulation
Ramström Contamination of oral wounds with saliva and bacteria
Ingerslev et al. Efficacy of recombinant factor VIIa (rVIIa) in surgical procedures in haemophilia A patients with inhibitors and congenital factor VII deficiency
CA2086835A1 (fr) Variants d'activateur tissulaire du plasminogene a clairance reduite
IE890270L (en) Proteins derived from human alpha 2 plasmin inhibitor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed